Masanori Onda, M.D., Ph.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 37, Room 5110
Bethesda, MD 20892
301-451-8577

Dr. Onda is focusing on the pre-clinical development of recombinant immunotoxins (RITs) as new immunotherapy reagents. RITs are genetically modified forms of Pseudomonas exotoxin A that are targeted to cancer cells by the Fv portion of antibodies. These RITs are now in clinical trials and have produced many complete remissions in cancer.

As a staff scientist, Dr. Onda uses protein engineering to make these proteins more useful in patients by decreasing their immunogenicity so more treatment cycles can be given before antibodies develop in the patients. New RITs were designed by identifying and silencing the major B cell epitopes. These new RITs are being developed for clinical trials.

Areas of Expertise
immunotherapy, recombinant immunotoxin, antibody engineering, immunogenicity, B cell epitope

New Approach to Cancer Therapy: Recombinant Immunotoxins - Reducing the immunogenicity of protein therapeutics - Reducing the immunogenicity of PE38-based immunotoxins - Identification of human B lymphocyte epitopes

New Target for Mesothelioma and Gynecological Malignancies: Mesothelin - Soluble mesothelin is a useful biomarker for mesothelioma - New antibody for mesothelin and MPF

Investigating New Molecular Targets for Immunotoxin (CAPC, PATE, etc.) New target for Osteosarcoma and Neuroblastoma: - 8H9 immunotoxin New Target for Lymphoma: - CD30 immunotoxin - CD30 antibody, which does not bind shedding epitopes

Selected Publications
  1. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, Hassan R, Pastan I.
    J. Immunol.. 177: 8822-34, 2006. [ Journal Article ]
  2. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I.
    Clin. Cancer Res.. 12: 4225-31, 2006. [ Journal Article ]
  3. Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.
    J. Immunol.. 193: 48-55, 2014. [ Journal Article ]
  4. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
    Proc. Natl. Acad. Sci. U.S.A.. 109: 11782-7, 2012. [ Journal Article ]
  5. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.
    Proc. Natl. Acad. Sci. U.S.A.. 108: 5742-7, 2011. [ Journal Article ]

Dr. Onda is staff scientist in the Laboratory Molecular Biology, Center for Cancer Research. He obtained his M.D. in 1989. He obtained his Ph.D. from the University of Tokyo in 1997. He received medical training (orthopedic surgery) at the University of Tokyo, Hitachi General Hospital, and Mitsui Memorial Hospital. He received research training at the Institute of Medical Science, University of Tokyo, and at NIH.

Summary

Dr. Onda is focusing on the pre-clinical development of recombinant immunotoxins (RITs) as new immunotherapy reagents. RITs are genetically modified forms of Pseudomonas exotoxin A that are targeted to cancer cells by the Fv portion of antibodies. These RITs are now in clinical trials and have produced many complete remissions in cancer.

As a staff scientist, Dr. Onda uses protein engineering to make these proteins more useful in patients by decreasing their immunogenicity so more treatment cycles can be given before antibodies develop in the patients. New RITs were designed by identifying and silencing the major B cell epitopes. These new RITs are being developed for clinical trials.

Areas of Expertise
immunotherapy, recombinant immunotoxin, antibody engineering, immunogenicity, B cell epitope

Research

New Approach to Cancer Therapy: Recombinant Immunotoxins - Reducing the immunogenicity of protein therapeutics - Reducing the immunogenicity of PE38-based immunotoxins - Identification of human B lymphocyte epitopes

New Target for Mesothelioma and Gynecological Malignancies: Mesothelin - Soluble mesothelin is a useful biomarker for mesothelioma - New antibody for mesothelin and MPF

Investigating New Molecular Targets for Immunotoxin (CAPC, PATE, etc.) New target for Osteosarcoma and Neuroblastoma: - 8H9 immunotoxin New Target for Lymphoma: - CD30 immunotoxin - CD30 antibody, which does not bind shedding epitopes

Publications

Selected Publications
  1. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, Hassan R, Pastan I.
    J. Immunol.. 177: 8822-34, 2006. [ Journal Article ]
  2. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I.
    Clin. Cancer Res.. 12: 4225-31, 2006. [ Journal Article ]
  3. Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.
    J. Immunol.. 193: 48-55, 2014. [ Journal Article ]
  4. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
    Proc. Natl. Acad. Sci. U.S.A.. 109: 11782-7, 2012. [ Journal Article ]
  5. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.
    Proc. Natl. Acad. Sci. U.S.A.. 108: 5742-7, 2011. [ Journal Article ]

Biography

Dr. Onda is staff scientist in the Laboratory Molecular Biology, Center for Cancer Research. He obtained his M.D. in 1989. He obtained his Ph.D. from the University of Tokyo in 1997. He received medical training (orthopedic surgery) at the University of Tokyo, Hitachi General Hospital, and Mitsui Memorial Hospital. He received research training at the Institute of Medical Science, University of Tokyo, and at NIH.